Antimuscarinics for treatment of overactive bladder.
For many years, antimuscarinic drugs have been the first-line pharmacological treatment for urgency, frequency, and urge incontinence, all symptoms of the disorder termed overactive bladder. Antimuscarinic treatment is not always effective and is associated with side-effects that limit its clinical use. The clinical significance of the effects of antimuscarinic drugs has been questioned lately. In this review, the rationale for the use of these drugs in the management of overactive bladder is re-examined and the results of treatment are discussed. I conclude that these drugs are the only treatment with undisputed effectiveness in the treatment of overactive bladder. They may not be the perfect treatment for all patients with this disorder, but their value for individual patients should not be underestimated. Further clinical trials with improvement in quality of life as the primary endpoint are needed and may give a fair reflection of the clinical value of antimuscarinic drugs.
Andersson
Karl-Erik
KE
Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden. Karl-Erik.Andersson@klinfarm.lu.se
D002986:Clinical Trials as Topic; D006801:Humans; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000378:metabolism; D016896:Treatment Outcome; D001745:Urinary Bladder Diseases / Q000188:drug therapy*
D018727:Muscarinic Antagonists; D011976:Receptors, Muscarinic